Moderna said on Monday that its combination vaccine that targets COVID-19 and the flu was more effective than their current separate vaccines for both viruses, according to new late-stage clinical trial data.

The pharmaceutical giant is the first company to release Phase 3 clinical trial data on a combination flu-COVID vaccine, leading the industry over rivals such as Novavax and Pfizer.

Recommended Stories

COVID-19 vaccines: The latest on recommendations and public attitudes

What comes next when the COVID-19 vaccines are ready?

What you need to know about the Johnson & Johnson coronavirus vaccine headed toward approval